Aldeyra Therapeutics Inc. (ALDX) Financial Statements (2025 and earlier)

Company Profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 29,881,520229,790,98977,858,31144,425,83047,357,472
Cash and cash equivalents   229,790,98977,858,31144,425,83047,357,472
Short-term investments 29,881,520  28,938,545 
Other undisclosed cash, cash equivalents, and short-term investments     (28,938,545) 
Prepaid expense340,388     
Other undisclosed current assets147,469,945151,141,5932,961,7815,200,95730,742,99547,411,814
Total current assets:147,810,333181,023,113232,752,77083,059,26875,168,82594,769,286
Noncurrent Assets
Operating lease, right-of-use asset510,814249,265351,863233,310201,007
Property, plant and equipment5,76419,27932,48759,925148,449235,225
Deferred costs      
Other undisclosed noncurrent assets      86,644
Total noncurrent assets:516,578268,544384,350293,235349,456321,869
TOTAL ASSETS:148,326,911181,291,657233,137,12083,352,50375,518,28195,091,155
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,874,52114,199,51011,543,0558,516,40312,681,4248,473,176
Accounts payable1,338,057133,6251,019,702381,638808,3023,051,678
Accrued liabilities5,536,46414,065,88510,523,3538,134,76511,873,1225,421,498
Deferred revenue     
Debt15,146,546911,763 3,659,776226,328 
Other undisclosed current liabilities239,183249,265229,607233,310  
Total current liabilities:22,260,25015,360,53811,772,66212,409,48912,907,7528,473,176
Noncurrent Liabilities
Long-term debt and lease obligation15,000,00014,923,09015,628,93511,434,45614,528,212 
Long-term debt, excluding current maturities15,000,00014,923,09015,503,70311,434,45614,528,212 
Liabilities, other than long-term debt271,631     
Operating lease, liability271,631 125,232  
Other undisclosed noncurrent liabilities (9,000,000) (125,232)   
Total noncurrent liabilities:6,271,63114,923,09015,628,93511,434,45614,528,212 
Total liabilities:28,531,88130,283,62827,401,59723,843,94527,435,9648,473,176
Equity
Equity, attributable to parent119,795,030151,008,029205,735,52359,508,55848,082,31786,617,979
Common stock59,19658,56058,08138,66728,65726,244
Additional paid in capital513,994,982507,770,045500,369,444296,385,619247,409,793225,136,127
Accumulated other comprehensive income (loss) (103,938)  5,866(9,224)
Accumulated deficit(394,259,148)(356,716,638)(294,692,002)(236,915,728)(199,361,999)(138,535,168)
Total equity:119,795,030151,008,029205,735,52359,508,55848,082,31786,617,979
TOTAL LIABILITIES AND EQUITY:148,326,911181,291,657233,137,12083,352,50375,518,28195,091,155

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(42,794,083)(62,679,987)(56,219,536)(34,666,755)(56,506,553)(39,699,151)
Other undisclosed operating loss    (1,754,265)(6,567,754) 
Operating loss:(42,794,083)(62,679,987)(56,219,536)(36,421,020)(63,074,307)(39,699,151)
Nonoperating income (expense)5,251,573655,351(1,556,738)(1,611,974)937,503805,906
Investment income, nonoperating7,323,0082,349,449185,363292,2241,541,349952,698
Interest and debt expense(2,071,435)(1,694,098)(1,742,101)(1,904,198)(603,846)(146,792)
Loss from continuing operations before equity method investments, income taxes:(39,613,945)(63,718,734)(59,518,375)(39,937,192)(62,740,650)(39,040,037)
Other undisclosed income from continuing operations before income taxes   1,742,1011,904,198603,846 
Loss from continuing operations before income taxes:(39,613,945)(63,718,734)(57,776,274)(38,032,994)(62,136,804)(39,040,037)
Income tax benefit    479,2651,309,973 
Loss from continuing operations:(39,613,945)(63,718,734)(57,776,274)(37,553,729)(60,826,831)(39,040,037)
Loss before gain (loss) on sale of properties:(57,776,274)(37,553,729)(60,826,831)(39,040,037)
Other undisclosed net income2,071,4351,694,098    
Net loss:(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)(39,040,037)
Other undisclosed net income attributable to parent     146,792
Net loss available to common stockholders, diluted:(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)(38,893,245)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)(39,040,037)
Other comprehensive income (loss)103,938(103,938) (5,866)15,0908,607
Comprehensive loss:(37,438,572)(62,128,574)(57,776,274)(37,559,595)(60,811,741)(39,031,430)
Other undisclosed comprehensive income, net of tax, attributable to parent     146,792
Comprehensive loss, net of tax, attributable to parent:(37,438,572)(62,128,574)(57,776,274)(37,559,595)(60,811,741)(38,884,638)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: